Clinical trial · Observational
Immunologic Profile of Peritoneal Cancer
Immunologic, Cellular, and Anti-microbial Profiling of Intraperitoneal Chemotherapy
NCT03230240CI-TRIAL-00047285unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To ascertain immunologic profile of peritoneal cavity and its relationship to immediate postsurgical outcome (morbidity or the treatment) and long-term outcome (time to recurrence and survival).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinomatosis | Carcinomatosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HIPEC | Drug | Hyperthermic Intraperitoneal Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- HIPEC
- description
- Patients with carcinomatosis or other peritoneal surface malignancy
- interventionNames
- Drug: HIPEC
Primary outcomes (1)
- measure
- In vitro growth of Staph Aureus and Escherichia coli measured in millimeters of colony forming unit on Agar plate
- timeFrame
- 1 year after operation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * HIPEC pt Exclusion Criteria: * absent consent
References
Publications (1)
- RESULTFranko J, Brahmbhatt R, Tee M, Raman S, Ferrel B, Gorvet M, Andres M. Cellular Immunoprofile of Peritoneal Environment During a HIPEC Procedure. Ann Surg Oncol. 2020 Dec;27(13):5005-5013. doi: 10.1245/s10434-020-08870-3. Epub 2020 Jul 21. PMID 32696309